{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigb5kgtx3milqlgp47k64adltynnx74tg2if55w5uhunxwdfwwa4a",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mktkjit45dx2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigoebio3uq5g4runryh7rlfqsiymgapk2ektjf3bfyboupg5mvpv4"
    },
    "mimeType": "image/jpeg",
    "size": 43627
  },
  "path": "/news/2026-05-fda-daily-idvynso-tablet-hiv.html",
  "publishedAt": "2026-05-01T22:00:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has approved Merck's Idvynso (doravirine/islatravir), a new, once-daily, two-drug single tablet for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA",
  "title": "FDA approves once-daily Idvynso tablet for treating HIV"
}